These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7664348)

  • 41. Anticancer therapy using glucuronate modified long-circulating liposomes.
    Oku N
    Adv Drug Deliv Rev; 1999 Nov; 40(1-2):63-73. PubMed ID: 10837780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes.
    Sugiyama I; Sadzuka Y
    Curr Drug Discov Technol; 2011 Dec; 8(4):357-66. PubMed ID: 22034853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liposomal modification with uronate, which endows liposomes with long circulation in vivo, reduces the uptake of liposomes by J774 cells in vitro.
    Namba Y; Oku N; Ito F; Sakakibara T; Okada S
    Life Sci; 1992; 50(23):1773-9. PubMed ID: 1598066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting drug release from liposomes.
    Lindner LH; Hossann M
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):111-23. PubMed ID: 20047152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoliposome targeting to CD4+ cells in human blood.
    Phillips NC; Tsoukas C
    Cancer Detect Prev; 1990; 14(3):383-90. PubMed ID: 2386976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liposomes in the treatment of infections.
    Bakker-Woudenberg IA; Storm G; Woodle MC
    J Drug Target; 1994; 2(5):363-71. PubMed ID: 7704480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo evaluation of novel pH-sensitive mPEG-Hz-Chol conjugate in liposomes: pharmacokinetics, tissue distribution, efficacy assessment.
    Chen D; Jiang X; Liu J; Jin X; Zhang C; Ping Q
    Artif Cells Blood Substit Immobil Biotechnol; 2010 May; 38(3):136-42. PubMed ID: 20337549
    [No Abstract]   [Full Text] [Related]  

  • 48. Electron microscopic studies on tissue distribution of lipid microspheres used as drug delivery carriers.
    Shoji Y; Mizushima Y; Yanagawa A; Yonaha T
    Drugs Exp Clin Res; 1985; 11(9):601-9. PubMed ID: 3880047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liposomal drug formulations in the treatment of rheumatoid arthritis.
    van den Hoven JM; Van Tomme SR; Metselaar JM; Nuijen B; Beijnen JH; Storm G
    Mol Pharm; 2011 Aug; 8(4):1002-15. PubMed ID: 21634436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Measurement of carbon clearance in mice as toxicity parameter for liposomal preparations.
    Fichtner I; Kniest A; Arndt D
    In Vivo; 1992; 6(1):113-7. PubMed ID: 1627737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Basic study and application of functional liposomes].
    Oku N
    Yakugaku Zasshi; 1995 Jul; 115(7):483-98. PubMed ID: 7562396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum independent liposome uptake by mouse liver.
    Liu F; Liu D
    Biochim Biophys Acta; 1996 Jan; 1278(1):5-11. PubMed ID: 8611606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues.
    Allen TM; Hansen C; Rutledge J
    Biochim Biophys Acta; 1989 May; 981(1):27-35. PubMed ID: 2719971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats.
    Takeuchi H; Kojima H; Yamamoto H; Kawashima Y
    J Control Release; 2000 Aug; 68(2):195-205. PubMed ID: 10925128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor accumulation of novel RES-avoiding liposomes.
    Oku N; Namba Y; Okada S
    Biochim Biophys Acta; 1992 Jun; 1126(3):255-60. PubMed ID: 1637853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci.
    Bakker-Woudenberg IA
    Int J Antimicrob Agents; 2002 Apr; 19(4):299-311. PubMed ID: 11978501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design of liposomes for circumventing the reticuloendothelial cells.
    Mumtaz S; Ghosh PC; Bachhawat BK
    Glycobiology; 1991 Nov; 1(5):505-10. PubMed ID: 1726577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade.
    Parr MJ; Bally MB; Cullis PR
    Biochim Biophys Acta; 1993 Jun; 1168(2):249-52. PubMed ID: 8504161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice.
    Oku N; Doi K; Namba Y; Okada S
    Int J Cancer; 1994 Aug; 58(3):415-9. PubMed ID: 8050822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rates of systemic degradation and reticuloendothelial system (RES) uptake of thermosensitive liposome encapsulating cisplatin in rats.
    Iga K; Ogawa Y; Toguchi H
    Pharm Res; 1993 Sep; 10(9):1332-7. PubMed ID: 8234172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.